Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

Currently, 15 randomized controlled trials (RCTs) have been designed to investigate whether neoadjuvant therapy (NAT) benefits patients with resectable pancreatic adenocarcinoma (R-PA) compared to surgery alone. Five of them have acquired results so far; however, corresponding conclusions have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao-Qi, Li, Jing, Tan, Chun-Lu, Chen, Yong-Hua, Zheng, Zhen-Jiang, Liu, Xu-Bao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611436/
https://www.ncbi.nlm.nih.gov/pubmed/36310705
http://dx.doi.org/10.4251/wjgo.v14.i10.1903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611436/
https://www.ncbi.nlm.nih.gov/pubmed/36310705
http://dx.doi.org/10.4251/wjgo.v14.i10.1903

Ejemplares similares